Matthew R. Smith
Led ARASENS and SPARTAN, trials that established darolutamide triplet therapy and apalutamide for prostate cancer.
Overview
Matthew Smith was principal investigator of ARASENS, which showed darolutamide added to androgen deprivation and docetaxel improves survival in metastatic hormone-sensitive prostate cancer, and of SPARTAN, which established apalutamide for non-metastatic castration-resistant disease. He has led landmark studies of bone loss and denosumab in men on hormone therapy.
Pages like this
not linked directly; found by shared links- PersonAndrew J. Armstrong
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tags prostate, trialist.
- PersonChristopher J. Sweeney
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tags prostate, trialist.
- ProductDarolutamide
Shares ARASENS, Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer.
- PersonKim N. Chi
Shares Androgen receptor, Prostate cancer and the tags prostate, trialist.
- PersonA. Oliver Sartor
Shares Prostate cancer and the tags prostate, trialist.
- PersonAnthony V. D'Amico
Shares Androgen deprivation & AR pathway inhibitors, Prostate cancer and the tag prostate.
- PersonMaha Hussain
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tag prostate.
- ProductFlutamide
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer.